In this issue:
Issue 121 -2016 50-year The impact of estimated prenatal exposure to particulate matter of ≤2.5μm in diameter in the development of childhood asthma was explored in 736 children born at ≥37 weeks' gestation. Overall, distributed lag models, adjusting for child age, sex and maternal education, race/ethnicity (84% of mothers were from ethnic 'minorities'), smoking, stress, atopy and prepregnancy obesity, revealed a significant association between particulate matter exposure during 16-25 weeks' gestation and the development of early childhood asthma; sex-stratified analyses showed that a significant association was only present in boys.
Comment: In this study, the authors correlated exposure to air pollution based on satellite images with a diagnosis of asthma at age 6 years. They report an effect of in utero exposure to air pollution with an increased risk of developing asthma; an effect only observed in boys. The authors spell out their main weakness -they can't confidently distinguish prenatal from postnatal exposure. The accompanying editorial points out that gestational exposure in animal models is associated with airway abnormalities. Bottom line: exposure to increased levels of air pollution during weeks 16-25 of gestation is associated with the development of childhood asthma.
Reference: Am J Respir Crit Care Med 2015; 192(9) :1052-9 Abstract
Prenatal maternal psychological stress and childhood asthma and wheezing Authors: van de Loo KFE et al.
Summary:
This was a meta-analysis of ten observational studies reporting on relationships between prenatal maternal psychological stress and childhood respiratory morbidity. The overall meta-analysis showed that children of mothers with some form of psychological stress during pregnancy had a higher prevalence of wheezing, asthma or other respiratory symptoms than those of mothers without psychological stress during pregnancy (pooled OR 1.56 [95% CI 1.36, 1.80]). Subgroup analyses of stress exposure, perceived stress, asthma and wheezing yielded similar findings.
Comment: When in utero exposure to air pollution has an adverse effect on lung development, what is the influence of maternal psychological stress during pregnancy on developing childhood asthma and wheezing? A group of Dutch researchers identified more than 10 studies on maternal stress during pregnancy, like the death of a husband, death of a child, exposure to violence or maternal depression. They concluded that future studies need to account for the impact of maternal psychological stress, because of their bottom line: children from mothers who suffered psychological distress during pregnancy had a 50% increased risk of developing wheeze, asthma and other respiratory symptoms. Comment: The evidence that exposure to air pollution increases asthma symptoms and exacerbations/flare ups is strong. The question whether air pollution causes asthma will probably be answered in future cohort studies using personal air monitoring devices as the authors of the accompanying editorial suggest. In this study the authors used data from 14,000 participants from four cohort studies to approximate an answer. Their take-home message is that reduction in air pollution could help reduce childhood asthma because of their bottom line: exposure to air pollution increases the risk of developing asthma by age 14 years.
Reference: Lancet Respir Med 2015;3(12):933-42 Abstract
Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years Authors: Stokholm J et al. Summary: Recurrent asthma-like symptoms lasting ≥3 days in 72 children were treated with oral azithromycin 10 mg/kg/day (n=79 episodes) or placebo (n=79 episodes) for 3 days in this RCT. Compared with placebo, azithromycin significantly shortened the mean duration of respiratory episodes after treatment (primary outcome; 3.4 vs. 7.7 days [p<0.0001]). Compared with starting treatment on or after day 6, starting before day 6 was associated with a significantly greater reduction in respiratory episode duration (83% vs. 36% [p<0.0001]). Clinical adverse events did not differ significantly between the azithromycin and placebo arms (p=0.30); post-treatment bacterial resistance patterns were not assessed.
Comment:
The researchers of the Copenhagen Asthma in Childhood study had previously published that both viruses and bacteria were associated with asthma-like symptoms in the first 3 years of life. Backing their own observations, they now report on a RCT of azithromycin for wheezing in young children. Jonathan Grigg warns us in the accompanying editorial that this trial doesn't justify the widespread use of azithromycin for troublesome respiratory symptoms; however, the bottom line is: azithromycin reduced the duration of asthmalike symptoms in young children either through antimicrobial or anti-inflammatory action. Comment: These British researchers reviewed the data on 4231 patients who underwent bronchodilator reversibility testing. Working on the hypothesis that patients with reversible airways disease (e.g. asthma) have better survival than patients with nonreversible airways disease (e.g. emphysema), they correlated the results of bronchodilator reversibility with mean survival. Men and people with a larger baseline FEV 1 had slightly better survival. They suggest an improvement of 8% in the FEV 1 may be the most appropriate criterion to define reversibility, because -bottom line -an improvement in FEV 1 of >8% predicted is associated with a significant survival advantage.
Reference: Lancet Respir
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Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. This prospective NZ cohort study investigated the impact of simple guidelinebased asthma management using an ACT (Asthma Control Test)-based 'step-up' regimen on asthma control in 93 primary-care patients with inadequately controlled asthma. The regimen was associated with good control (score >19) in 75% of the participants, with a mean ACT score increase of 6.0 (p<0.001) independent of baseline ICS (inhaled corticosteroid) use.
Comment: This short scientific letter details a study performed in a population of patients with asthma managed by NZ general practitioners. The authors tested the hypothesis that a stepwise increase of asthma medications improves asthma outcomes. All patients with an ACT score of <19 were offered an increase in their treatment from as-needed salbutamol to ICS plus salbutamol or from ICS to ICS/ LABA (long-acting β-agonist). This simple intervention achieved asthma control, as defined by an ACT score of 19 or greater, in 75% of the patients, with a mean increase of 6 points. Bottom line: a 'step-up' regimen based on ACT scores results in improved asthma control.
Reference: Respirology 2015;20(3):504-6 Abstract
A repeated short educational intervention improves asthma control and quality of life Authors: Plaza V et al.
Summary:
Adults with mild-to-moderate persistent uncontrolled asthma (n=230) were randomised by centre to an asthma educational programme based on repeated short interventions (four face-to-face sessions with administration of a written personalised action plan and training on inhaler technique at 3-month intervals) or usual clinical practice group for 1 year; specialised centres using a standard educational programme comprised a gold-standard group. While there were significant improvements in ACT scores in all three groups (p<0.001), compared with the usual clinical practice group, the intervention and gold standard groups had significantly greater increases (p=0.042) as well as fewer exacerbations and greater increases in QOL scores.
Comment: As Louis-Philippe Boulet points out in the accompanying editorial, education to self-manage asthma is an essential component in asthma management; however, it is met by barriers at patient, doctor and organisational levels. The above Spanish trial may be encouraging, as the authors report on a short (10-minute initial and 6-minute follow-up) intervention to deliver tailored, face-to-face asthma education for self-management. The authors showed a significant improvement in the ACT score. Bottom line: this short intervention may be able to bridge the gap between acknowledging self-management and enabling patients to manage their asthma themselves.
